#65 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Texas’s adoption of “total THC” calculations for hemp products means clinicians must counsel patients that smokable hemp products legally sold as low-THC alternatives may actually deliver significant Delta-9 THC levels when consumed, potentially causing unexpected psychoactive effects and drug interactions. This regulatory change clarifies the actual THC exposure patients receive from these products, enabling more accurate risk assessment and dosing discussions in clinical encounters. Clinicians should update their counseling to reflect that the labeled THC content on hemp products may not represent the active THC patients inhale, particularly important for patients with THC-sensitive conditions or those taking medications affected by cannabinoid metabolism.
Texas has implemented new hemp regulations that will ban smokable hemp products from retail shelves by the end of March, based on a “total THC” calculation methodology that includes tetrahydrocannabinolic acid (THCA) in addition to active Delta-9 THC. This regulatory shift reflects growing recognition that THCA converts to psychoactive Delta-9 THC when heated through smoking or vaping, making the distinction between “hemp” and “cannabis” products increasingly meaningless at the point of consumption. The total THC approach aligns Texas with federal standards and addresses a significant loophole that allowed high-THCA hemp products to be marketed and sold legally despite producing psychoactive effects comparable to traditional cannabis. For clinicians, this means that patients seeking cannabis-derived products in Texas will face reduced access to smokable forms and may be directed toward regulated medical cannabis or alternative delivery methods if they reside in the state. Patients who have been using over-the-counter hemp-derived products should be counseled before March to discuss alternative options and any potential therapeutic gaps, while clinicians should stay informed about changing state-level regulations that affect their patients’ ability to access or obtain cannabis products.
“What Texas is doing with the total THC calculation is scientifically sound, but the real clinical issue is that we’re banning smokable hemp while patients who could benefit from whole-plant, lower-dose cannabis are left with fewer options and less certainty about what they’re actually consuming.”
🤖 Texas’s adoption of total THC calculations that include THCA for hemp product regulation represents an important step toward standardizing measurement methods across states, though clinicians should recognize this creates complexity in counseling patients about actual psychoactive exposure. The conversion of THCA to Delta-9 THC through heating is chemically sound, but the regulatory shift may leave patients confused about products they’ve already purchased or obtained in neighboring states with different standards. Healthcare providers should be aware that smokable hemp products have proliferated partly because of loopholes in federal regulations defining hemp by Delta-9 THC content alone, and that enforcement variations between states mean patients may have inconsistent access depending on geography. When discussing cannabis use with patients, particularly those in border regions or who order online, clinicians should clarify that “hemp-derived” products are not necessarily low-THC or non-intoxicating, and should counsel patients that unregulated products
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: